Emergent Biosolutions (EBS) Stock Price, Quote & News

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botul...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 240 631 3200

Fax: 240 631 3203

Website: www.emergentbiosolutions.com

Address:

300 Professional Drive, Suite 400, Gaithersburg, United States

SuperGreenToday Aug. 4 at 3:12 AM

$EBS Share Price: $7.41 Contract Selected: Jan 15, 2027 $5 Calls Buy Zone: $0.68 – $0.84 Target Zone: $1.14 – $1.40 Potential Upside: 59% ROI Time to Expiration: 164 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Kawasaki1 Aug. 4 at 2:54 AM

$EBS Lots of oddball green candles at the end of trading recently...Something huge to be announced afterhours. Perhaps on Wednesday?

1 · Reply

billywilliamz Aug. 3 at 3:05 PM

$EBS

0 · Reply

mickley32 Aug. 3 at 1:55 PM

$EBS

0 · Reply

LynnRiggs479 Aug. 3 at 11:54 AM

$EBS Emergent BioSolutions continues restructuring while focusing on biodefense products and specialty pharmaceutical operations.

0 · Reply

History101 Aug. 2 at 9:10 PM

$EBS from June 16, 2026: more competition in the emergency opoid OD space: $AMPH drug approved https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-spray-opioid-overdose

1 · Reply

CoffeeRocks Aug. 2 at 12:43 AM

$CODX $AEMD $VRAX $GOVX $EBS Looks like he’s gonna be rich 🤑 “R” 🔜 https://www.aljazeera.com/amp/news/2026/7/31/dr-congo-ebola-epidemic-becomes-worlds-second-largest-outbreak

0 · Reply

DarleneCornell186 Aug. 1 at 12:09 PM

$EBS Emergent BioSolutions continues restructuring while focusing on biodefense and specialty pharmaceutical products. Government contracts remain an important revenue source.

0 · Reply

JudyPhillips648 Aug. 1 at 5:46 AM

$EBS Emergent BioSolutions continues restructuring its operations following pandemic-related volatility. Government contracts, pipeline execution, and operational efficiency remain important recovery drivers.

0 · Reply